New data confirms long-term benefits of Vyepti

Adding to the bank of positive clinical evidence for its already-marketed drug, Danish CNS specialist Lundbeck (LUND: CO) today released new data confirming long-term benefit of treatment with Vyepti (eptinezumab) in migraine prevention.

The DELIVER extension study findings were presented at the 65th Annual Scientific Meeting of the American Headache Society (AHS) now taking place in Austin, Texas.

The DELIVER study confirmed the effectiveness of Vyepti in reducing migraine frequency and severity in adults with two-four previous treatment failures. The patients completing the placebo-controlled period in the DELIVER study were offered to participate in a 48-week open-label, dose-blinded extension period, and these data have now become available